000166134 001__ 166134
000166134 005__ 20240229123220.0
000166134 0247_ $$2doi$$a10.1371/journal.pone.0242814
000166134 0247_ $$2pmid$$apmid:33264342
000166134 037__ $$aDKFZ-2020-02642
000166134 041__ $$aeng
000166134 082__ $$a610
000166134 1001_ $$aRehm, Martin$$b0
000166134 245__ $$aRelationship between cardiac biomarker concentrations and long-term mortality in subjects with osteoarthritis.
000166134 260__ $$aSan Francisco, California, US$$bPLOS$$c2020
000166134 3367_ $$2DRIVER$$aarticle
000166134 3367_ $$2DataCite$$aOutput Types/Journal article
000166134 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1607678799_5875
000166134 3367_ $$2BibTeX$$aARTICLE
000166134 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166134 3367_ $$00$$2EndNote$$aJournal Article
000166134 520__ $$aOsteoarthritis (OA) is associated with adverse cardio-metabolic features. N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponins T and I (hs-cTnT and hs-cTnI) are well-characterized cardiac markers and provide prognostic information. The objective was to assess the association of cardiac biomarker concentrations with long-term mortality in subjects with OA. In a cohort of 679 OA subjects, undergoing hip or knee replacement during 1995/1996, cardiac biomarkers were measured and subjects were followed over 20 years. During a median follow-up of 18.4 years, 332 (48.9%) subjects died. Median of hs-cTnT, hs-cTnI, and NT-proBNP at baseline was 3.2 ng/L, 3.9 ng/L, and 96.8 ng/L. The top quartile of NT-proBNP was associated with increased risk of mortality (Hazard Ratio (HR) 1.79, 95% confidence interval (CI) 1.17-2.73) after adjustment for covariates including troponins (hs-cTnT HR 1.30 (95% CI 0.90-1.89), hs-cTnI HR 1.32 (95% CI 0.87-2.00) for top category). When biomarker associations were evaluated as continuous variables, only NT-proBNP (HR per log-unit increment 1.34, 95% CI 1.16-1.54) and hs-cTnI (HR 1.38, 95% CI 1.11-1.72) showed robust results. Elevated cardiac biomarker concentrations predicted an increased risk of long-term mortality and strongest for NT-proBNP and hs-cTnI. These results might help to identify subjects at risk and target preventive efforts early.
000166134 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000166134 588__ $$aDataset connected to CrossRef, PubMed,
000166134 7001_ $$aBüchele, Gisela$$b1
000166134 7001_ $$aPeter, Raphael Simon$$b2
000166134 7001_ $$aBrenner, Rolf Erwin$$b3
000166134 7001_ $$aGünther, Klaus-Peter$$b4
000166134 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$udkfz
000166134 7001_ $$aKoenig, Wolfgang$$b6
000166134 7001_ $$00000-0002-3563-2791$$aRothenbacher, Dietrich$$b7
000166134 773__ $$0PERI:(DE-600)2267670-3$$a10.1371/journal.pone.0242814$$gVol. 15, no. 12, p. e0242814 -$$n12$$pe0242814 -$$tPLOS ONE$$v15$$x1932-6203$$y2020
000166134 909CO $$ooai:inrepo02.dkfz.de:166134$$pVDB
000166134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000166134 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000166134 9141_ $$y2020
000166134 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPLOS ONE : 2018$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2020-08-32
000166134 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-32
000166134 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-32
000166134 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x0
000166134 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000166134 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000166134 980__ $$ajournal
000166134 980__ $$aVDB
000166134 980__ $$aI:(DE-He78)HD01-20160331
000166134 980__ $$aI:(DE-He78)C070-20160331
000166134 980__ $$aI:(DE-He78)C120-20160331
000166134 980__ $$aUNRESTRICTED